Navigation Links
Anthrax inhibitor counteracts toxin, may lead to new therapeutics

Researchers from Rensselaer Polytechnic Institute and the University of Toronto have designed a nanoscale assembly of molecules that successfully counteracts and inhibits anthrax toxin in animal and laboratory experiments. The novel approach used to neutralize anthrax toxin could be applied in designing potent therapeutics for a variety of pathogens and toxins, according to the researchers.

Anthrax toxin, secreted by the anthrax bacterium, is made of proteins and toxic enzymes that bind together to inflict damage on a host organism. The inhibitor, which is described by the Rensselaer-Toronto team in the April 23 online edition of the journal Nature Biotechnology, works by preventing the assembly of toxic enzyme components, thereby blocking the formation of fully assembled anthrax toxin and neutralizing its activity.

The inhibitor protected rats from anthrax toxin in the study.

"Our eventual goal is to use the inhibitor as a human therapeutic for anthrax exposure, one that can stop the toxin from functioning inside the body," says Ravi Kane, the Merck Associate Professor of Chemical and Biological Engineering at Rensselaer and a principal investigator of the project. "Combining the inhibitor with antibiotic therapy may increase the likelihood of survival for an infected person."

The 2001 intentional release of anthrax spores via postal mail in the United States led to increased research on possible therapeutics and vaccines to treat toxins that could be used as biological weapons. The current treatment for anthrax exposure is antibiotics, but inhalation anthrax still has a fatality rate of 75 percent even after antibiotics are given, according to the Centers for Disease Control and Prevention. Antibiotics slow the progression of infection by targeting the bacteria, but do not counter the advanced destructive effects of anthrax toxin in the body.

Anthrax toxin is a polyvalent protein complex in that it displays multiple copies of
'"/>

Source:Rensselaer Polytechnic Institute


Page: 1 2 3

Related biology news :

1. Study Models Impact Of Anthrax Vaccine
2. Anthrax test, developed by army and CDC, receives FDA approval
3. Anthrax inhibitors identified by Burnham team
4. Anthrax stops body from fighting back, study shows
5. Anthrax spores may survive water treatment
6. Anthrax attack posed greater potential threat than thought
7. Anthrax paralyzes immune cells with lethal toxin, UF research shows
8. Protease inhibitors reach beyond HIV
9. UNC scientists discover new role for protein as fundamental inhibitor of cell movement
10. Small molecule inhibitor of cholera discovered
11. Enzyme inhibitors block replication of SARS virus
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Anthrax inhibitor counteracts toxin may lead new therapeutics

(Date:11/21/2014)... REDMOND, Wash. , Nov. 20, 2014 ... access for the Internet of Things (IoT), today announced ... position of chief operating officer. Previously a strategic advisor ... marketing, finance, and operations. Mr. Traynor is based out ... . He reports to Chris Muench , ...
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
(Date:11/7/2014)... Researchers led by Dr. Debra Auguste, associate professor, ... at The City College of New York, have ... treatment for one of the most aggressive forms ... (TNBCs) have a high mortality rate owing to ... effective therapeutic options. However, Professor Auguste,s team, discovered ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... The March of Dimes has extended its Prematurity Campaign ... address preterm birth globally. The expansion, announced at the ... the national action plan being created during the two-day ... birth. "The March of Dimes Prematurity Campaign has ...
... shot of youthful vigor in a stem cell experiment by ... for research on new treatments for age-related degenerative conditions such ... a new study to be published June 15 in an ... identified two key regulatory pathways that control how well adult ...
... has received $400,000 from the National Oceanic and Atmospheric ... system for the Mid-Atlantic region, spanning the waters from ... to the continental shelf. Nearly 25 percent of the ... initiative is part of the national Integrated Ocean Observing ...
Cached Biology News:March of Dimes announces Prematurity Campaign expansion at Surgeon General's conference 2March of Dimes announces Prematurity Campaign expansion at Surgeon General's conference 3Stem cell researchers give old muscle new pep 2Stem cell researchers give old muscle new pep 3Stem cell researchers give old muscle new pep 4UD nets NOAA funding for Mid-Atlantic ocean observing 2
(Date:11/27/2014)... USA (PRWEB) November 26, 2014 Biomedical ... accuracy, additive systems to enable 3D manufacture at the ... road conditions are among finalists in nine categories for ... The awards are sponsored by SPIE, the international ... Media . , Winners will be announced by industry ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 2014 ... is a professional and in-depth research report on ... information, like its definition, classification, application, and industry ... report covers the international market analysis, including China’s ... the US, Europe, Asia, China, Japan etc. regions) ...
(Date:11/26/2014)... YORK , Nov. 26, 2014 The ... may indicate the company is looking to expand in ... further sales.  The healthcare market research firm says that  ... to Kalorama Information,s biennial survey of the IVD market ... and any change in its composition would likely affect ...
(Date:11/26/2014)... November 26, 2014 On January, 14, ... Baltimore and Washington D.C. science community to the UMBC ... event, sponsored by the Protein Society, will take place ... Center, Room 312. Through discussion, presentations and workshops, ... importance of proteins, their role in the industry and ...
Breaking Biology Technology:Finalists Named for 2015 Prism Awards for Photonics Innovation 2Finalists Named for 2015 Prism Awards for Photonics Innovation 3Finalists Named for 2015 Prism Awards for Photonics Innovation 4Finalists Named for 2015 Prism Awards for Photonics Innovation 5Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2
... Renowned Clinicians in the Fields of Cancer and Women,s Health ... to Best ... Address Current Medical Needs, REHOVOT, Israel and ... ROSG) announced,today the establishment of its Medical Advisory Board. Rosetta ...
... Pa., Feb. 4 Centocor, Inc. announced today,that ... 1275),has been accepted for review by the U.S. ... adult patients with chronic moderate to severe plaque,psoriasis. ... a novel,mechanism of action that targets the cytokines ...
... Aricept Prescription Rates, According to a New Report from Decision ... ... Feb. 4 Decision Resources, one of the,world,s leading research and ... owns a dominating,42.4% patient share for first-line treatment of newly diagnosed ...
Cached Biology Technology:Rosetta Genomics Establishes Medical Advisory Board 2Rosetta Genomics Establishes Medical Advisory Board 3Rosetta Genomics Establishes Medical Advisory Board 4Rosetta Genomics Establishes Medical Advisory Board 5Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 2Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 3Eisai/Pfizer's Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimer's Disease 2Eisai/Pfizer's Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimer's Disease 3
... LAS-3000 imaging system combines new CCD ... interface, providing significantly improved system sensitivity ... The system is especially dedicated to ... system for Western blotting applications.,Fuiji's LAS-3000 ...
This kit is designed to select cells labeled with biotinylated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
... The Fujifilm Life Science LAS-3000mini ... especially dedicated to chemiluminescence applications, and ... blotting applications., Fuiji 's LAS-3000 provides ... and digitization. , Glowell calibration standards ...
... FLIM system combines the space and time dimensions ... of the optical microscope to open new horizons ... light source for excitation, the decay of a ... of the decay measured. Subtle changes in ...
Biology Products: